[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK3628670T3 - Saltform til ezh2-hæmning - Google Patents

Saltform til ezh2-hæmning Download PDF

Info

Publication number
DK3628670T3
DK3628670T3 DK19180479.8T DK19180479T DK3628670T3 DK 3628670 T3 DK3628670 T3 DK 3628670T3 DK 19180479 T DK19180479 T DK 19180479T DK 3628670 T3 DK3628670 T3 DK 3628670T3
Authority
DK
Denmark
Prior art keywords
salt form
ezh2 inhibition
ezh2
inhibition
salt
Prior art date
Application number
DK19180479.8T
Other languages
English (en)
Inventor
Kevin Wayne Kuntz
Kuan-Chun Huang
Hyeong Wook Choi
Kristen Sanders
Steven Mathieu
Arani Chanda
Frank Fang
Original Assignee
Epizyme Inc
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc, Eisai R&D Man Co Ltd filed Critical Epizyme Inc
Application granted granted Critical
Publication of DK3628670T3 publication Critical patent/DK3628670T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
DK19180479.8T 2012-04-13 2013-04-11 Saltform til ezh2-hæmning DK3628670T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261624215P 2012-04-13 2012-04-13
EP16191716.6A EP3184523B1 (en) 2012-04-13 2013-04-11 N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[l,1'-biphenyl]-3-carboxamide hydrobromide for use in the treatment of a cell proliferative disorder of the hematologic system

Publications (1)

Publication Number Publication Date
DK3628670T3 true DK3628670T3 (da) 2022-12-05

Family

ID=49328166

Family Applications (3)

Application Number Title Priority Date Filing Date
DK16191716.6T DK3184523T3 (da) 2012-04-13 2013-04-11 N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4' -(morphofinomethyl)-[1,1'-biphenyl]-3-carboxamidhydrobromid til anvendelse i behandlingen af en sygdom med celleproliferation i det hæmatologiske system.
DK13774979.2T DK2836491T3 (da) 2012-04-13 2013-04-11 Saltform af en human histonmethyltransferase ezh2-inhibitor
DK19180479.8T DK3628670T3 (da) 2012-04-13 2013-04-11 Saltform til ezh2-hæmning

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK16191716.6T DK3184523T3 (da) 2012-04-13 2013-04-11 N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4' -(morphofinomethyl)-[1,1'-biphenyl]-3-carboxamidhydrobromid til anvendelse i behandlingen af en sygdom med celleproliferation i det hæmatologiske system.
DK13774979.2T DK2836491T3 (da) 2012-04-13 2013-04-11 Saltform af en human histonmethyltransferase ezh2-inhibitor

Country Status (26)

Country Link
US (6) US9394283B2 (da)
EP (4) EP3628670B1 (da)
JP (3) JP6255382B2 (da)
KR (4) KR102744039B1 (da)
CN (2) CN104603130B (da)
AU (2) AU2013245878B2 (da)
BR (1) BR112014025508B1 (da)
CA (1) CA2870005C (da)
CY (2) CY1119383T1 (da)
DK (3) DK3184523T3 (da)
ES (3) ES2931316T3 (da)
HR (2) HRP20170295T1 (da)
HU (3) HUE060881T2 (da)
IL (4) IL282732B2 (da)
IN (1) IN2014DN09068A (da)
LT (2) LT3184523T (da)
MX (1) MX362339B (da)
NZ (1) NZ700761A (da)
PL (3) PL2836491T3 (da)
PT (3) PT3628670T (da)
RS (2) RS55690B1 (da)
RU (1) RU2658911C2 (da)
SG (3) SG11201406468YA (da)
SI (2) SI2836491T1 (da)
SM (2) SMT201900501T1 (da)
WO (1) WO2013155317A1 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
EP2780013A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
AU2013216721B2 (en) 2012-02-10 2017-09-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
KR20200062386A (ko) 2012-04-13 2020-06-03 에피자임, 인코포레이티드 암 치료용 병용 요법
AU2013245878B2 (en) 2012-04-13 2017-10-12 Eisai R&D Management Co.Ltd. Salt form of a human histone methyltransferase EZH2 inhibitor
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
LT2908823T (lt) 2012-10-15 2019-10-25 Epizyme Inc Vėžio gydymo būdai
NZ706738A (en) * 2012-10-15 2018-10-26 Epizyme Inc Substituted benzene compounds
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
JP6373973B2 (ja) 2013-04-30 2018-08-15 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Zesteホモログ2エンハンサー阻害剤
CA2917463A1 (en) 2013-07-10 2015-01-15 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
WO2015023915A1 (en) 2013-08-15 2015-02-19 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
DK3057962T3 (da) 2013-10-16 2023-11-06 Epizyme Inc Hydrochloridsaltform til ezh2-hæmning
JP2016533364A (ja) * 2013-10-18 2016-10-27 エピザイム,インコーポレイティド 癌を処置する方法
WO2015077193A1 (en) * 2013-11-19 2015-05-28 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
CN116019921A (zh) 2013-12-06 2023-04-28 Epizyme股份有限公司 用于治疗癌症的组合疗法
EP4252851A3 (en) 2014-06-17 2023-11-22 Epizyme Inc Ezh2 inhibitors for treating lymphoma
DK3157928T3 (da) 2014-06-20 2019-05-20 Constellation Pharmaceuticals Inc Krystallinske former af 2-((4s)-6-(4-chlorphenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamid
BR112017007738B1 (pt) 2014-10-16 2023-04-11 Epizyme, Inc Método para determinar a probabilidade de eficácia de um tratamento e método para triagem da eficácia de um tratamento compreendendo um inibidor de ezh2
KR20240035908A (ko) 2014-11-17 2024-03-18 에피자임, 인코포레이티드 암을 치료하기 위한 방법
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ezh2抑制劑
EA201792304A1 (ru) 2015-04-20 2018-03-30 Эпизайм, Инк. Комбинированная терапия для лечения рака
WO2016201328A1 (en) 2015-06-10 2016-12-15 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma
CN108025191A (zh) 2015-08-24 2018-05-11 Epizyme股份有限公司 治疗癌症的方法
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ezh2抑制劑
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
JP2019503391A (ja) 2016-01-29 2019-02-07 エピザイム,インコーポレイティド 癌を処置するための併用療法
AU2017273726B2 (en) * 2016-06-01 2023-10-19 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
EP3529242A1 (en) 2016-10-19 2019-08-28 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
WO2018137639A1 (zh) * 2017-01-25 2018-08-02 恩瑞生物医药科技(上海)有限公司 一种组蛋白甲基转移酶ezh2抑制剂、其制备方法及其医药用途
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
AU2018275123A1 (en) 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
JP7399079B2 (ja) 2017-09-05 2023-12-15 エピザイム,インコーポレイティド 癌を処置するための併用療法
WO2020011607A1 (en) 2018-07-09 2020-01-16 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
CN114555112A (zh) 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
IL294108A (en) * 2019-12-20 2022-08-01 Epizyme Inc Crystalline hydrobromide salt of a ezh2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer
WO2022208552A1 (en) * 2021-03-31 2022-10-06 Msn Laboratories Private Limited, R&D Center Crystalline forms of [1,1'-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1) and process for its preparation thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733729A (ja) 1993-07-26 1995-02-03 Kirin Brewery Co Ltd N−シアノ−n′−置換−アリールカルボキシイミダミド化合物の製造法
ATE180468T1 (de) 1993-12-27 1999-06-15 Eisai Co Ltd Anthranilsäure derivate
DE19516776A1 (de) 1995-05-10 1996-11-14 Boehringer Ingelheim Int Chromatin-Regulatorgene
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
JP3906935B2 (ja) 1995-12-18 2007-04-18 杏林製薬株式会社 N−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
JP2002525352A (ja) 1998-09-30 2002-08-13 ザ、プロクター、エンド、ギャンブル、カンパニー 2−置換ケトアミド
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
KR100828982B1 (ko) 2000-12-28 2008-05-14 시오노기세이야쿠가부시키가이샤 칸나비노이드 2형 수용체 친화 작용을 갖는 피리돈 유도체
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
DE60329981D1 (de) 2002-02-19 2009-12-24 Shionogi & Co Antipruriginosa
TW200306155A (en) 2002-03-19 2003-11-16 Du Pont Benzamides and advantageous compositions thereof for use as fungicides
US7442685B2 (en) 2003-06-13 2008-10-28 The University Of North Carolina At Chapel Hill DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
CA2561977A1 (en) * 2004-03-30 2005-10-13 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
EP1765994B1 (en) 2004-06-01 2009-11-18 The University of North Carolina at Chapel Hill Reconstituted histone methyltransferase complex and methods of identifying modulators thereof
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
ATE494548T1 (de) 2005-06-02 2011-01-15 Univ North Carolina Reinigung, charakterisierung und wiederherstellung einer ubiquitin-e3-ligase
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
PL1940821T3 (pl) 2005-10-19 2013-08-30 Gruenenthal Gmbh Nowe ligandy receptora waniloidowego i ich zastosowanie do wytwarzania leków
EP1951672B1 (en) 2005-10-21 2011-05-25 Merck Sharp & Dohme Corp. Potassium channel inhibitors
WO2007053480A2 (en) 2005-10-28 2007-05-10 The University Of North Carolina At Chapel Hill Protein demethylases comprising a jmjc domain
KR20080080173A (ko) 2005-12-14 2008-09-02 브리스톨-마이어스 스큅 컴퍼니 세린 프로테아제 억제제로서 유용한 6-원 헤테로사이클
AU2006336552B2 (en) 2006-01-20 2012-12-20 The University Of North Carolina At Chapel Hill Diagnostic and therapeutic targets for leukemia
CA2650329A1 (en) 2006-05-15 2008-06-19 Irm Llc Terephthalamate compounds and compositions, and their use as hiv integrase inhibitors
US20070287706A1 (en) 2006-05-18 2007-12-13 Dickson John K Jr Certain substituted quinolones, compositions, and uses thereof
JP2010505958A (ja) 2006-10-10 2010-02-25 バーンハム インスティトゥート フォー メディカル リサーチ 神経防護作用組成物および方法
EP2114898A2 (en) 2007-02-16 2009-11-11 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
EP2137158A4 (en) 2007-02-28 2012-04-18 Methylgene Inc LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS)
WO2008113006A1 (en) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
DE102007017884A1 (de) 2007-04-13 2008-10-16 Grünethal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
US20090012031A1 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan EZH2 Cancer Markers
DE102007047737A1 (de) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
AU2008319308B2 (en) 2007-10-31 2013-01-31 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
JP5511680B2 (ja) 2007-12-19 2014-06-04 キャンサー・リサーチ・テクノロジー・リミテッド ピリド[2,3−b]ピラジン−8−置換化合物及びその使用
WO2009124137A2 (en) 2008-04-01 2009-10-08 Mount Sinai School Of Medicine Of New York University Method of suppressing gene transcription through histone lysine methylation
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
WO2010017355A2 (en) 2008-08-08 2010-02-11 New York Blood Center Small molecule inhibitors of retroviral assembly and maturation
FR2934995B1 (fr) 2008-08-14 2010-08-27 Sanofi Aventis Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique
EP2411007A4 (en) 2009-03-27 2012-12-05 Uab Research Foundation MODULATION OF MEDIATION TRANSLATION BY IRES SEQUENCES
US20110021362A1 (en) 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
CA2784899A1 (en) 2009-12-30 2011-07-07 Avon Products, Inc. Topical lightening composition and uses thereof
JP5864546B2 (ja) * 2010-05-07 2016-02-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC インダゾール
US8637509B2 (en) * 2010-05-07 2014-01-28 Glaxosmithkline Llc Azaindazoles
UA110112C2 (uk) * 2010-05-07 2015-11-25 Глаксосмітклайн Ллс Індоли
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
CN103261890B (zh) 2010-09-10 2016-04-06 Epizyme股份有限公司 人ezh2抑制剂及其应用方法
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2012075080A1 (en) 2010-12-01 2012-06-07 Glaxosmithkline Llc Indoles
CA2819625A1 (en) 2010-12-03 2012-06-07 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) * 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
RU2704445C2 (ru) 2012-03-12 2019-10-28 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
KR20200062386A (ko) 2012-04-13 2020-06-03 에피자임, 인코포레이티드 암 치료용 병용 요법
AU2013245878B2 (en) 2012-04-13 2017-10-12 Eisai R&D Management Co.Ltd. Salt form of a human histone methyltransferase EZH2 inhibitor
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
LT2908823T (lt) 2012-10-15 2019-10-25 Epizyme Inc Vėžio gydymo būdai
DK3057962T3 (da) 2013-10-16 2023-11-06 Epizyme Inc Hydrochloridsaltform til ezh2-hæmning

Also Published As

Publication number Publication date
KR20150002730A (ko) 2015-01-07
LT3184523T (lt) 2020-02-10
ES2745016T3 (es) 2020-02-27
HUE031976T2 (en) 2017-08-28
JP2018199740A (ja) 2018-12-20
US11491163B2 (en) 2022-11-08
JP2015512942A (ja) 2015-04-30
KR20200066380A (ko) 2020-06-09
ES2617379T3 (es) 2017-06-16
AU2013245878A1 (en) 2014-10-30
US20210137936A1 (en) 2021-05-13
HRP20191653T1 (hr) 2020-02-21
MX2014012380A (es) 2015-07-23
US20180243316A1 (en) 2018-08-30
RU2658911C2 (ru) 2018-06-26
PL3628670T3 (pl) 2023-02-20
RU2014145544A (ru) 2016-06-10
SG10201912109QA (en) 2020-02-27
US20170143729A1 (en) 2017-05-25
SMT201900501T1 (it) 2019-11-13
JP2018002742A (ja) 2018-01-11
US20150065503A1 (en) 2015-03-05
DK3184523T3 (da) 2019-08-19
SG10201608577RA (en) 2016-12-29
IL266165B (en) 2021-06-30
JP6255382B2 (ja) 2017-12-27
HUE060881T2 (hu) 2023-04-28
PT3184523T (pt) 2019-09-26
CY1122883T1 (el) 2022-03-24
IL282732B (en) 2022-12-01
PL3184523T3 (pl) 2019-12-31
KR20220123339A (ko) 2022-09-06
US20190269692A1 (en) 2019-09-05
EP3184523A1 (en) 2017-06-28
PT3628670T (pt) 2022-12-02
AU2018200168B2 (en) 2019-08-29
LT2836491T (lt) 2017-03-27
JP6634058B2 (ja) 2020-01-22
EP2836491A4 (en) 2015-09-16
WO2013155317A1 (en) 2013-10-17
RS55690B1 (sr) 2017-07-31
IL296199B2 (en) 2024-12-01
EP3628670B1 (en) 2022-10-12
DK2836491T3 (da) 2017-03-06
SMT201700132T1 (it) 2017-05-08
CN104603130B (zh) 2018-04-27
US9872862B2 (en) 2018-01-23
AU2018200168A1 (en) 2018-02-01
IL296199A (en) 2022-11-01
RS59392B1 (sr) 2019-11-29
US9394283B2 (en) 2016-07-19
CN108358899B (zh) 2021-07-27
SI2836491T1 (sl) 2017-06-30
SG11201406468YA (en) 2015-01-29
PL2836491T3 (pl) 2017-08-31
US20230140327A1 (en) 2023-05-04
EP3184523B1 (en) 2019-06-19
US10821113B2 (en) 2020-11-03
IN2014DN09068A (da) 2015-05-22
US10245269B2 (en) 2019-04-02
EP2836491B1 (en) 2016-12-07
PT2836491T (pt) 2017-02-08
AU2013245878B2 (en) 2017-10-12
CA2870005C (en) 2021-06-22
IL235045B (en) 2019-05-30
EP4190777A1 (en) 2023-06-07
IL296199B1 (en) 2024-08-01
EP2836491A1 (en) 2015-02-18
KR20250005505A (ko) 2025-01-09
HRP20170295T1 (hr) 2017-04-21
IL282732B2 (en) 2023-04-01
CY1119383T1 (el) 2018-02-14
MX362339B (es) 2019-01-11
IL235045A0 (en) 2014-12-31
SI3184523T1 (sl) 2020-04-30
KR102744039B1 (ko) 2024-12-17
EP3628670A1 (en) 2020-04-01
KR102120883B1 (ko) 2020-06-09
BR112014025508B1 (pt) 2020-11-17
CA2870005A1 (en) 2013-10-17
IL282732A (en) 2021-06-30
CN104603130A (zh) 2015-05-06
HUE045353T2 (hu) 2019-12-30
IL266165A (en) 2019-06-30
NZ700761A (en) 2016-09-30
CN108358899A (zh) 2018-08-03
ES2931316T3 (es) 2022-12-28
KR102438340B1 (ko) 2022-08-30

Similar Documents

Publication Publication Date Title
DK3628670T3 (da) Saltform til ezh2-hæmning
DK3057962T3 (da) Hydrochloridsaltform til ezh2-hæmning
HK1222387A1 (zh) 作為 抑制劑的芳基吡咯並吡啶衍生的化合物
LT3181567T (lt) Pirazolpirimidino junginiai kaip kinazės slopikliai
LT2841428T (lt) Dnr-pk inhibitoriai
CO6970602A2 (es) Inhibidores de quinasa
EP2710007A4 (en) Kinase inhibitors
ZA201503041B (en) Gdf-8 inhibitors
ME02626B (me) Inhibitori neprilisina
LT2895484T (lt) Gliukozilceramido sintazės inhibitoriai
DK2903618T3 (da) Rho-kinase-inhibitorer
HUE036259T2 (hu) Inhibitor vegyületek
RS56821B1 (sr) Inhibitori histon demetilaze
HUE037048T2 (hu) Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására
SMT201600114B (it) Inibitori di beta-secretasi
EP2948450A4 (en) METALLOENZYMINHIBITORVERBINDUNGEN
DK2804858T3 (da) Metalloenzym-inhibitorforbindelser
DK3395357T3 (da) Sammensætning til kontrolleret ovariestimulering
CO6880068A2 (es) Aminoquinazolinas como inhibidores de quinasa
HK1208450A1 (en) Nampt inhibitors nampt
DK2804611T3 (da) Chitosanafledte forbindelser
EP2858975A4 (en) FBXO3 INHIBITORS
EP2847201A4 (en) 6-oxo-purin-phosphoribosyl INHIBITORS
HK1217481A1 (zh) 作為 抑制劑的氨基吡啶衍生的化合物
DK2745928T3 (da) Fremgangsmåde til emulsionsfremstilling